All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?
Can HMA maintenance therapy improve eligibility for HSCT?
Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation.
Editorial theme │ Maintenance therapy for AML
Maintenance therapy has been proven very efficacious at improving long-term patient outcomes and reducing relapse in the acute lymphoblastic leukemia (ALL) setting. Thus, research into the role of...
SOHO 2019 | In what ways can the immune system be involved in treating patients with AML?
At SOHO 2019, we spoke to Dr Farhad Ravandi from The University of Texas, MD Anderson Cancer Center, about ways the immune system can be involved in treating...
Subscribe to get the best content related to AML delivered to your inbox